Transfixing Endovenous Thermal Ablation (TEThA) for varicose veins treatment - A prospective single-arm study.
Nara Medeiros Cunha deMelo Vasconcelos, Marcelo Halfen Grill, Gabriela de Oliveira Buril et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, single-arm study evaluated Transfixing Endovenous Thermal Ablation (TEThA) in 22 patients with varicose veins across CEAP classes C2–C6. Quality-of-life and clinical scores were assessed before treatment and at 6 weeks and 6 months. Scores improved significantly, including CIVIQ-14 from 30.95 to 22.76 (p = .013), while the study reported no significant complications, thrombotic events, or reinterventions. The findings suggest potential benefit, but the uncontrolled design does not establish comparative effectiveness.
Key findings
- CIVIQ-14 improved from 30.95 to 22.76 (p = .013).
- AVVQ improved from 36.43 to 23.49 (p = .012), and rVCSS from 7.73 to 4.18 (p = .014).
- CEAP score improved from 3.09 to 1.94 (p = .002).
- No significant complications, thrombotic events, or need for reintervention occurred.
Why it matters
Varicose vein treatment aims to improve symptoms and quality of life while limiting procedural harms. These results provide preliminary evidence that TEThA may improve patient-reported and clinical scores, with no significant safety events reported in this small study. The findings are relevant to evaluating the technique, but do not show how it compares with other treatments.
What to keep in mind
The study was single-arm and included only 22 patients, so it cannot establish comparative effectiveness; follow-up assessments extended to 6 months.